SCHEMBL10152397

SCHEMBL10152397

CC(C)(C)c1ccc2c(C(C)(C)C)n[nH]c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 5/20 0.47
GSK3B P49841 3/20 0.43
FGFR1 P11362 2/20 0.43
FLT3 P36888 2/20 0.43
CLK4 Q9HAZ1 2/20 0.43
CHEK1 O14757 2/20 0.43
PRKAA1 Q13131 2/20 0.43
PLK4 O00444 1/20 0.43
AURKA O14965 1/20 0.43
CHUK O15111 1/20 0.43
PDPK1 O15530 1/20 0.43
JAK2 O60674 1/20 0.43
ROCK2 O75116 1/20 0.43
MAP4K4 O95819 1/20 0.43
PAK4 O96013 1/20 0.43
CHEK2 O96017 1/20 0.43
ABL1 P00519 1/20 0.43
NTRK1 P04629 1/20 0.43
PRKCG P05129 1/20 0.43
INSR P06213 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10220256 0.88 KIF11 (0.56) KIF11GSK3BTRPA1MAP2K4MAPK1
SCHEMBL21018486 0.85 KIF11 (0.47) KIF11GSK3BFGFR1FLT3CLK4
SCHEMBL18848183 0.81 ITK (0.47) KIF11CHEK1CDK1CDK2ITK
SCHEMBL12962020 0.81 KIF11 (0.47) KIF11GSK3BFGFR1FLT3CLK4
SCHEMBL84515 0.81 PDPK1 (0.55) KIF11GSK3BFGFR1FLT3CLK4
SCHEMBL24076277 0.81 DAO (0.38) KIF11ALDH1A1MITFTP53KMT2A
SCHEMBL10219959 0.80 MAP2K4 (0.51) ITKKMT2AMAP2K4MAPK1MAPK6
SCHEMBL23478517 0.80 KIF11 (0.46) KIF11GSK3BFGFR1FLT3CLK4
SCHEMBL14738709 0.80 KIF11 (0.46) KIF11GSK3BFGFR1FLT3CLK4
SCHEMBL10220162 0.80 GSK3B (0.44) GSK3BCHEK1DYRK1ATRPA1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200039943-A1 COMPOUNDS, DEVICES, AND USES THEREOF SIGILON THERAPEUTICS, INC. 2020-02-06 US disclosed
US-9828373-B2 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-11-28 US disclosed
US-9828373-B2 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-11-28 US disclosed
US-20170121323-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-05-04 US disclosed
US-20170121323-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-05-04 US disclosed
US-8148531-B2 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CHROMA THERAPEUTICS LTD. (GB) 2012-04-03 US disclosed
US-8044211-B2 P38 MAP kinase inhibitors CHROMA THERAPEUTICS LTD. (GB) 2011-10-25 US disclosed
US-8044211-B2 P38 MAP kinase inhibitors CHROMA THERAPEUTICS LTD. (GB) 2011-10-25 US disclosed
US-20090203711-A1 Inhibitors of P38 Map Kinase CHROMA THERAPEUTICS LTD. (GB) 2009-08-13 US disclosed
US-20090131461-A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CHROMA THERAPEUTICS LTD. (GB) 2009-05-21 US disclosed
US-20090099185-A1 P38 Map Kinase Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2009-04-16 US disclosed
US-20090099185-A1 P38 Map Kinase Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200039943-A1 COMPOUNDS, DEVICES, AND USES THEREOF SLC10A1, SLCO1B3, SLC5A1 KIF11 2456/4885GSK3B 231/4885FGFR1 782/4885
US-20090099185-A1 P38 Map Kinase Inhibitors MAPK1, CNKSR1, MAPK3 KIF11 4666/4885GSK3B 770/4885FGFR1 682/4885
US-20090203711-A1 Inhibitors of P38 Map Kinase MAPK1, MAPK3, CNKSR1 KIF11 4375/4885GSK3B 181/4885FGFR1 1936/4885
US-20170121323-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF CDK6, CDK4, CDK7 KIF11 2899/4885GSK3B 488/4885FGFR1 1241/4885
US-20090131461-A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CDK1, AURKC, CSNK1G3 KIF11 2164/4885GSK3B 163/4885FGFR1 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.